✦ LIBER ✦

C30. Methodologic issues in pharmacoeconomic evaluations of HMG-CoA reductase inhibitors used in the treatment of hyperlipidemia

✍ Scribed by S.X. Kong; S.K. Gandhi; S.Y. Crawford

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The role of HMG-CoA reductase inhibitors

✍ Jean Paul Deslypere 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 909 KB

Safety and Efficacy of HMG-CoA Reductase

✍ Scott R. Penzak; Susan K. Chuck; Gregory V. Stajich 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 35 KB

The Safety Evaluation of Fluvastatin, an

✍ Howard A. Hartman; Laurie A. Myers; Morton Evans; Rodney L. Robison; Robert G. E 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Clinical efficacy of fluvastatin, a new

✍ T. Teramoto; Y. Goto 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Treatment with HMG-CoA reductase inhibit

✍ Masanori Kuwabara; Hiroaki Kitaoka; Makoto Okawa; Takashi Furuno; Masanori Nishi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

The expanding role of HMG-CoA reductase

✍ Robert Chilton; Robert A. O'Rourke 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 906 KB